ERBB2 and breast cancer: We should note that according to a study in 125 women with HER2+ early-stage breast cancer receiving sequential anthracycline/trastuzumab, echocardiography-derived GLS was the most optimal prognostic marker even when compared to feature-tracking-derived GLS and global circumferential strain from CMR [72].